GV participated in a round that increased the on-demand healthcare service's overall funding to $107m, with the cash to go to expanding its operations.

SR One, AbbVie Ventures, Takeda Ventures and Pfizer Ventures all returned for the cancer and inflammatory disease drug developer's series B.

Blue Venture Fund took part in a $61.8m round for the testing services provider, and managing director Anna Haghgooie will join PWNHealth’s board.

Carrie Hurwitz Williams has been promoted from principal while Jennifer Carter will add the role to her vice-president of portfolio development, marketing and venture operations position.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

University hospital Charité’s sinus surgery spinout Fiagon Medical has been acquired for more than $70m, with Cascara Ventures and Donghai Securities also scoring exits.

Graphite Bio's first drug program will target sickle cell anaemia based on innovations in DNA editing from Stanford University.

Lilly Asia Ventures achieved an exit as the gastrointestinal and liver disease drug developer priced its initial public offering in the middle of its range.

Tencent Trusted Doctors has partnered China Resources' CR Capital fund to establish a healthcare industry fund focusing on the city of Chengdu.

The autoreactive and neuro-inflammatory disease therapy developer closed a $77.5m round co-led by Sanofi Ventures that took its total funding to more than $117m.